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ABSTRACT
Chikungunya virus (CHIKV) is a reemerging arbovirus responsible for outbreaks of infection throughout Asia and Africa, caus-
ing an acute illness characterized by fever, rash, and polyarthralgia. Although CHIKV infects a broad range of host cells, little is
known about how CHIKV binds and gains access to the target cell interior. In this study, we tested whether glycosaminoglycan
(GAG) binding is required for efficient CHIKV replication using CHIKV vaccine strain 181/25 and clinical isolate SL15649. Pre-
incubation of strain 181/25, but not SL15649, with soluble GAGs resulted in dose-dependent inhibition of infection. While pa-
rental Chinese hamster ovary (CHO) cells are permissive for both strains, neither strain efficiently bound to or infected mutant
CHO cells devoid of GAG expression. Although GAGs appear to be required for efficient binding of both strains, they exhibit
differential requirements for GAGs, as SL15649 readily infected cells that express excess chondroitin sulfate but that are devoid
of heparan sulfate, whereas 181/25 did not. We generated a panel of 181/25 and SL15649 variants containing reciprocal amino
acid substitutions at positions 82 and 318 in the E2 glycoprotein. Reciprocal exchange at residue 82 resulted in a phenotype
switch; Gly82 results in efficient infection of mutant CHO cells but a decrease in heparin binding, whereas Arg82 results in re-
duced infectivity of mutant cells and an increase in heparin binding. These results suggest that E2 residue 82 is a primary deter-
minant of GAG utilization, which likely mediates attenuation of vaccine strain 181/25.
IMPORTANCE
Chikungunya virus (CHIKV) infection causes a debilitating rheumatic disease that can persist for months to years, and yet there are
no licensed vaccines or antiviral therapies. Like other alphaviruses, CHIKV displays broad tissue tropism, which is thought to be influ-
enced by virus-receptor interactions. In this study, we determined that cell-surface glycosaminoglycans are utilized by both a vaccine
strain and a clinical isolate of CHIKV to mediate virus binding. We also identified an amino acid polymorphism in the viral E2 attach-
ment protein that influences utilization of glycosaminoglycans. These data enhance an understanding of the viral and host determi-
nants of CHIKV cell entry, which may foster development of new antivirals that act by blocking this key step in viral infection.
Chikungunya virus (CHIKV) is a reemerging arbovirus indig-enous to Africa and Asia that causes Chikungunya fever in
humans (1, 2). This illness is most often characterized by rapid
onset of fever, incapacitating polyarthralgia, rash, myalgia, and
headache (1–3). Although viremia is usually cleared 5 to 7 days
after infection, a characteristic feature of CHIKV disease is recur-
ring polyarthritis that can persist for months or years (4–8). Sev-
eral Aedes species of mosquitoes serve as vectors of CHIKV, in-
cluding A. aegypti and A. albopictus (9–12). CHIKV caused an
explosive outbreak of disease beginning in 2004 that expanded to
areas beyond the historical range of the virus, including Europe
and many islands in the Indian Ocean (1, 2, 13), and produced
more-severe illness than previously observed (14–17). CHIKV
continues to spread to new regions (18–22), and currently there
are no available vaccines or treatments for this disease (23).
CHIKV is a member of the Togaviridae and belongs to the Old
World Semliki Forest virus (SFV) group of arthritogenic alphavi-
ruses (reviewed in reference 24). The CHIKV genome is 11.8 kb
comprising a single-stranded, message-sense RNA molecule that
is capped and polyadenylated (25). Viral proteins are synthesized
as two independent polyprotein precursors that undergo proteo-
lytic cleavage by viral and cellular proteases. The virion is a 70-nm-
diameter, icosahedral, enveloped particle that contains three
structural proteins, a capsid protein and two glycoproteins, E1
and E2 (26–29). E1 and E2 form heterodimers that associate in
trimers, which constitute spikes on the viral envelope (28, 30). E1
is a class II viral fusion protein, while E2 mediates attachment of
the virus to cells and is the most likely candidate for engagement of
cell-surface receptors (29). After attachment and internalization,
CHIKV is thought to enter the endocytic pathway, where E1 me-
diates fusion of the viral and endosomal membranes (31). This
process is dependent on acidification of endosomal vesicles and
most likely occurs in early endosomes in both mammalian and
mosquito cells (13, 31–34).
Attachment to the host cell surface is the initial step in viral
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infection and a critical determinant of tissue tropism. Many vi-
ruses use adhesion strengthening to engage cells via low-affinity
tethering to common cell-surface molecules such as carbohy-
drates followed by binding to less-abundant, usually protein-
aceous molecules with higher affinity (35, 36). A diverse array of
viral pathogens, including adenovirus (37), coxsackievirus B3
variant PD (38), dengue virus (39), enterovirus 71 (40), herpes
simplex virus (41), HIV-1 (42), human papillomavirus (43), and
respiratory syncytial virus (44), use glycosaminoglycans (GAGs)
as attachment factors. GAGs are negatively charged, unbranched
linear carbohydrate polymers consisting of repeating disaccharide
units made of glucuronic acid or iduronic acid, linked to an amino
sugar, glucosamine or galactosamine. Types of GAGs include
heparan sulfate, keratan sulfate, chondroitin sulfate, and derma-
tan sulfate. GAGs are found on the surface of most mammalian
cell types and in the extracellular matrix. These molecules are
involved in a number of biological functions, including embry-
onic development, cell adhesion, proliferation, migration, wound
healing, and extracellular matrix assembly, among many others
(reviewed in references 45 and 46). Most GAG-protein interac-
tions are mediated between the negatively charged polysaccharide
chain or sulfate groups of the GAG and clusters of basic amino
acids, which may form a conformation-specific binding site, in the
protein ligand (46–49).
Certain strains of several alphaviruses, including eastern
equine encephalitis virus (EEEV) (50), Ross River virus (RRV)
(51), Sindbis virus (SINV) (52, 53), SFV (54), and Venezuelan
equine encephalitis virus (VEEV) (55), use glycosaminoglycans as
attachment receptors. During cell culture adaptation of many al-
phaviruses, basic amino acids in E2 glycoproteins are rapidly se-
lected (51–53, 55, 56). Concordantly, positively charged amino
acid substitutions in E2 are implicated in mediating interactions
with GAGs and in most cases with heparan sulfate (50–55, 57–62).
Heparan sulfate binding by alphaviruses and other viruses often
correlates with attenuation of disease in animal models (50, 55–
59, 63), likely due to rapid clearance of the virus from the circula-
tion of the infected animal (55, 58). However, natural isolates of
EEEV display dependence on GAGs for infection of cells in cul-
ture, which correlates with increased neurovirulence (50). In ad-
dition, several low-passage-number strains of VEEV also exhibit
different degrees of GAG dependence (62). Thus, GAG binding
might confer some replicative advantage during infection with
EEEV or VEEV and perhaps other alphaviruses as well. The role of
GAGs in replication of CHIKV clinical isolates is not clear.
In this study, we examined whether a clinical isolate (SL15649)
(64) or an attenuated, vaccine strain (181/25) (65) requires cell-
surface GAGs for efficient attachment to target cells and subse-
quent infection. Strain SL15649 was isolated from a CHIKV-
infected patient in Sri Lanka in 2006, has been minimally passaged
in cell culture, and is pathogenic in a mouse model of CHIKV
disease (64). Strain 181/25 was derived from strain AF15661,
which was isolated from a patient in Thailand in 1962. Strain
181/25 was developed as a vaccine candidate for CHIKV by adapt-
ing AF15561 to cell culture by 18 plaque-to-plaque passages in a
human lung fibroblast cell line (MRC-5) (65). In both mouse (76,
80) and nonhuman primate models, 181/25 is attenuated but im-
munogenic (65). In addition, administration of 181/25 protects
against CHIKV challenge in nonhuman primates (65). Although
181/25 (called TSI-GSD-218) was highly immunogenic in phase II
clinical trials, 8% of vaccinees developed mild, transient arthral-
gia, suggesting partial or unstable attenuation (66, 67). Gardner et
al. previously demonstrated that 181/25 infectivity was decreased
in GAG-deficient Chinese hamster ovary (CHO) cells, suggesting
that this laboratory-adapted strain is dependent on GAGs for in-
fectivity (76). Here, we expanded upon previous studies and
found that several GAGs competitively inhibit infectivity of
BHK-21 cells by 181/25 but not SL16549. In contrast, both 181/25
and SL15649 depend on cell-surface GAGs for binding and infec-
tion of CHO cells. Furthermore, we identified residue 82 in the E2
glycoprotein as a key determinant of GAG utilization and binding
to heparin by CHIKV. Collectively, these findings indicate that
vaccine strain 181/25 is more dependent on GAGs than SL15649
for infectivity and suggest a mechanism of attenuation for 181/25.
MATERIALS AND METHODS
Cells and reagents. BHK-21 cells (ATCC CCL-10) were maintained in
alpha minimal essential medium (MEM; Gibco) supplemented to con-
tain 10% fetal bovine serum (FBS) and 10% tryptose phosphate. Vero 81
cells (ATCC CCL-81) were maintained in MEM supplemented to con-
tain 5% FBS. Parental CHO-K1 and mutant CHO-pgsA745, CHO-
pgsB761, and CHO-pgsD677 cell lines were maintained in Ham’s F-12
nutrient mixture (Gibco) supplemented to contain 10% FBS. Media for
all cells were supplemented with 0.29 mg/ml L-glutamine (Gibco), 100
U/ml penicillin (Gibco), 100 g/ml streptomycin (Gibco), and 25 ng/ml
amphotericin B. Cells were maintained at 37°C in an atmosphere of 5%
CO2. Parental CHO-K1 and CHO-pgsA745 cell lines were provided by
Benhur Lee (University of California, Los Angeles). CHO-pgsB761 and
CHO-pgsD677 cell lines were provided by Mark Peeples (The Research
Institute at Nationwide Children’s Hospital) with permission from Jeffrey
Esko (University of California, San Diego). All chemicals were purchased
from Sigma unless otherwise noted.
Biosafety. All studies using viable SL15649 and any mutant virus were
conducted in a certified biological safety level 3 facility in biological safety
cabinets with protocols approved by Vanderbilt University Department
of Environment, Health, and Safety and the Vanderbilt Institutional Bio-
safety Committee.
Viruses. Virus stocks were generated from full-length wild-type (WT)
and mutant virus infectious cDNA clones as described in references 64
and 68. Plasmids containing virus cDNAs were linearized by digestion
with NotI-HF (NEB). Capped, full-length RNA transcripts were gener-
ated in vitro using mMessage mMachine SP6 transcription kits (Ambion)
and introduced into BHK-21 cells by electroporation using a Gene Pulser
electroporator (Bio-Rad). Culture supernatants were harvested 24 to 48 h
after electroporation and clarified by centrifugation at 855  g for 20 min.
Virus stocks were purified by ultracentrifugation of clarified supernatants
through a 20% sucrose cushion in TNE buffer (50 mM Tris-HCl [pH 7.2],
0.1 M NaCl, and 1 mM EDTA) at 115,000  g in a Beckman 32Ti rotor.
Virus pellets were resuspended in virus dilution buffer (VDB; RPMI me-
dium containing 20 mM HEPES [Gibco] supplemented to contain 1%
FBS), aliquoted, and stored at 70°C. Virus titers were determined by
plaque assay using Vero cells.
Assessment of CHIKV infectivity. BHK-21 cells (4  103 cells/well)
or CHO cells (8  103 cells/well) were seeded into wells of 48-well plates
(Costar) and incubated at 37°C for 24 h. Triplicate wells were inoculated
with various virus strains at a multiplicity of infection (MOI) of 2.5 (BHK-
21) or 10 (CHO) PFU/cell in VDB. Following adsorption at 37°C for 2 h,
the inoculum was removed, and cells were incubated at 37°C for 18 h in
complete medium containing 20 mM NH4Cl (to block subsequent
rounds of viral replication). Cells were washed twice with PBS, fixed in
100% ice-cold methanol, and incubated at 20°C for at least 20 min.
Infected cells were visualized using indirect immunofluorescence. Cells
were incubated in blocking buffer (phosphate-buffered saline [PBS;
Gibco] containing 5% FBS and 0.1% Triton X-100) at room temperature
for 1 h and stained with precleared anti-CHIKV immune ascetic fluid
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(ATCC VR-1241AF) diluted 1:1,500 and secondary Alexa 488 goat anti-
mouse antibody diluted 1:1,000 (Invitrogen), followed by addition of
DAPI (4=,6-diamidino-2-phenylindole) to visualize cell nuclei. All anti-
bodies were diluted in blocking buffer. For some experiments, cells were
visualized using an Axiovert 200 fluorescence microscope (Zeiss). Total
and CHIKV-infected cells were quantified using ImageJ software (69) in
two fields of view per well. For other experiments, cells were visualized
using an ImageExpress Micro XL imaging system (Molecular Devices) at
the Vanderbilt High-Throughput Screening Facility. Total and CHIKV-
infected cells were quantified using MetaExpress software (Molecular De-
vices) in two fields of view per well. No background stain was noted on
uninfected control monolayers.
Infectivity inhibition assays. Purified CHIKV virions were pretreated
with a range of dilutions of heparin, heparan sulfate, chondroitin sulfate
A, chondroitin sulfate A/C/E from shark, dermatan sulfate, or hyaluronic
acid at 4°C for 30 min before inoculation of BHK-21 monolayers with
virus-GAG mixtures. For some experiments, bovine serum albumin
(BSA) was included as a negative control. Following incubation at 37°C
for 2 h, the inoculum was removed, and cells were incubated at 37°C for 18
h in complete medium with 20 mM NH4Cl. Infectivity was quantified
using indirect immunofluorescence.
Flow cytometric analysis of virus binding to cells. The effect of sol-
uble GAGs on CHIKV binding to BHK-21 cells was determined by pre-
incubating virus with GAGs in VDB at various concentrations at 4°C for
30 min. BHK-21 monolayers were washed and detached using Cellstrip-
per (Cellgro), quenched with fluorescence-activated cell-sorting (FACS)
buffer (PBS supplemented to contain 2% FBS), pelleted at 600  g,
washed once with PBS, and pelleted a second time at 600  g. Cells (1 
105 to 3  105) were adsorbed with the virus-GAG mixtures at an MOI of
5 PFU/cell and incubated at 4°C for 30 min, washed twice in VDB, pel-
leted, and stained in VDB containing CHIKV-specific mouse monoclonal
antibody CHK-187 (provided by Michael Diamond, Washington Univer-
sity). Cells were washed twice in VDB, pelleted, and stained in VDB con-
taining Alexa Fluor 488-labeled goat anti-mouse IgG (Molecular Probes)
at 4°C for 30 min. Cells were washed twice in VDB, pelleted, and fixed in
FACS fix (PBS supplemented to contain 1% electron microscopy [EM]-
grade paraformaldehyde [Electron Microscopy Sciences]). Cell-associ-
ated fluorescence was quantified using an LSRII flow cytometer (BD Bio-
sciences, Vanderbilt University Flow Cytometry Shared Resource). The
mean fluorescence intensity (MFI) of forward- and side-scatter gated
populations was determined using FACSDiva software (BD Biosciences).
Binding of pretreated virus to BHK-21 cells was normalized to binding of
untreated virus controls and expressed as percent bound virus. Binding
assays were performed using triplicate samples with at least 5  103 cells
analyzed for each sample.
CHO cell monolayers were washed once with PBS and detached using
Cellstripper (Cellgro) at 37°C, quenched with FACS buffer, pelleted at
600  g, washed once with PBS, and pelleted a second time at 600  g.
Cells (1  105 to 3  105) were adsorbed with virus at an MOI of 5
PFU/cell at 4°C for 1 h. Bound virus was quantified using flow cytometry.
Binding of each virus to mutant CHO cells was normalized to virus bound
to parental CHO-K1 cells and expressed as percent bound virus.
Kinetic heparan sulfate protection assay. Purified virions of strain
181/25 were adsorbed to monolayers of BHK-21 cells (104) at an MOI of
2.5 PFU/cell. At 10 or 30 min prior to or 5, 10, 20, 30, or 45 min after
adsorption, either heparan sulfate (250 g/ml) or BSA (250 g/ml) was
added to the virus inoculum and rapidly mixed. Following incubation at
37°C for 2 h, the inoculum was removed, and cells were incubated at 37°C
for 18 h in complete medium with 20 mM NH4Cl. Infectivity was quan-
tified using indirect immunofluorescence.
Kinetic ammonium chloride protection assay. Monolayers of
BHK-21 cells (104) seeded in 48-well plates were adsorbed with virus
strains at an MOI of 2.5 PFU/cell and incubated at 37°C. At various times
after adsorption, the inoculum was removed, and cells were incubated in
complete medium containing 20 mM NH4Cl at 37°C for 18 h. Infectivity
was quantified using indirect immunofluorescence.
Generation of mutant viruses. Reciprocal single and double amino
acid substitutions in the E2 glycoprotein were introduced into plasmids
containing cDNAs of either strain 181/25 (p181/25 [68]) or SL15649
(pMH56.1 [64]) by PCR using mutagenic primers. Clones containing
desired mutations were identified by DNA sequencing (GenHunter and
Vanderbilt Sequencing Core) and digested with restriction endonu-
cleases (SmaI and XhoI for p181/25 and SfiI and XhoI for pMH56.1).
Mutagenized fragments were subcloned into unmodified versions of
p181/25 or pMH56.1. Sequences of subcloned fragments of each mutant
were determined to verify the fidelity of mutagenesis. Primer sequences
for mutagenesis and sequencing are available from the corresponding
author by request.
Genome-to-PFU ratios. The number of CHIKV genomes/ml for each
purified virus stock was determined using reverse transcription-quantita-
tive PCR (RT-qPCR). Viral RNA was extracted from 10 l of purified
virus stocks using TRIzol reagent (Life Technologies), purified using a
PureLink RNA Minikit (Life Technologies), and eluted into a final volume
of 100 l. Quantification of the number of genomes in each virus stock
was performed using a qScript XLT One-step RT-qPCR ToughMix kit
(Quanta Biosciences) according to the manufacturer’s instructions with
minor modifications. Each 20-l reaction mixture contained 5 l viral
RNA, 450 nM forward primer (SL15649for [874 5=-AAAGGGCAAACTC
AGCTTCAC-3=] or 181-25for [5=-AAAGGGCAAGCTTAGCTTCAC-
3=]), 900 nM reverse transcriptase and reverse primer (CHIKVrev [961
5=-GCCTGGGCTCATCGTTATTC-3=]), and 200 nM fluorogenic probe
(CHIKVprobe [899 5=-6-carboxyfluorescein {dFAM}-CGCTGTGATAC
AGTGGTTTCGTGTG-black hole quencher {BHQ}-3=]; Biosearch Tech-
nologies). Standard curves relating threshold cycle (CT) values to copies of
genomic RNA were generated from in vitro-transcribed genomic 181/25
or SL15649 RNA as described. Ten-fold dilutions of genomic RNA, from
1010 to 105 copies, were generated by calculating the number of genomes
from in vitro-transcribed RNA by dividing the mass (measured by spec-
trometry [Nanodrop; Thermo Scientific]) by the genome molecular mass.
RT-qPCR was performed using an Applied Biosystems 7500 Real-Time
PCR system (Life Technologies, Foster City, CA) under the following
cycling conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for
15 s, and 60°C for 60 s, with data acquisition in the FAM channel during
the 60°C step. The viral RNA concentration in each sample was deter-
mined by comparing CT values of samples to the appropriate standard
curve. Genome values per ml are expressed as the means of the results
from two wells for three samples. Genome/PFU ratios are expressed as the
mean number of genomes/ml divided by the mean number of PFU/ml for
three RNA replicates using values from three plaque assay titrations.
Heparin-agarose-binding assay. Heparin-coated agarose beads or
unconjugated beads were washed twice in PBS and twice in VDB. Washed
beads (0.075 ml) were mixed with 1  109 genomes of each virus in VDB
and incubated with gentle agitation at 4°C for 30 min. Beads were washed
three times in VDB and resuspended in 35 l of 1 sample buffer (50 mM
Tris-HCl [pH 6.8], 2% [wt/vol] sodium dodecyl sulfate [SDS], 1% -mer-
captoethanol, 6% [vol/vol] glycerol, 0.004% [wt/vol] bromophenol blue).
Samples containing 12.5% of the input virus in 20 l VDB were incubated
with an equivalent volume of 2 sample buffer. All samples were boiled
for 10 min, removed from the biosafety level 3 (BSL3) laboratory after
disinfection, and stored at 70°C. Samples were resolved by SDS-poly-
acrylamide gel electrophoresis (PAGE) in 10% polyacrylamide gels (Bio-
Rad) and transferred to an Immun-Blot polyvinylidene difluoride
(PVDF) membrane (Bio-Rad). Membranes were incubated at room tem-
perature for 1 h in blocking buffer (Tris-buffered saline [TBS] with 5%
powdered milk), followed by incubation with mouse monoclonal anti-
body specific for CHIKV E2 (CHK 48-G8; provided by Michael Diamond,
Washington University) diluted in TBS-T (TBS with 0.1% Tween 20) at
4°C overnight with gentle agitation. Membranes were washed with TBS-T
three times for 5 min each time and incubated for 1 to 2 h with goat
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anti-mouse secondary antibody conjugated to IRDye 800CW (Li-COR)
dye diluted 1:2,000 in TBS-T at room temperature. Following three 5-min
washes with TBS-T, membranes were rinsed twice with double-distilled
water and scanned using an Odyssey imaging system (Li-COR).
Structural and sequence analysis. The crystallographic structure of
the CHIKV E1/E2 trimer placed into the Sindbis virus cryo-EM map
(Protein Data Base [PDB] accession no. 2XFB [30]) was used as a template
to model the electrostatic surface potential of the E1/E2 trimers of
SL15649 and 181/25. Coot (70) was used to alter 12 of the 16 amino acids
within E2 that are located in the crystal structure from SL15649 to 181/25
residues using the lowest free-energy rotamers. Electrostatic surface po-
tentials for 181/25 and SL15649 were generated with the Adaptive Pois-
son-Boltzmann Solver (APBS) (71) using the PyMOL plug-in as imple-
mented in PyMOL under dielectric constants of 2.0 and 80.0 for protein
and solvent regions, respectively, and contoured at levels of  2.5 kT.
Amino acid sequences of the E2 protein from 158 CHIKV strains were
aligned using data obtained from the NIAID Virus Pathogen Database
and Analysis Resource (ViPR) (72) online through the web site at http:
//www.viprbrc.org.
Statistical analysis. Statistical analysis was performed using Graph-
Pad Prism (Graphpad). Soluble-GAG competition assays and time course
assays were evaluated for statistically significant differences by one-way
analysis of variance (ANOVA) followed by Dunnett’s post hoc test. Calcu-
lation of 50% inhibitory concentration (IC50) values with 95% confidence
intervals was facilitated using GraphPad Prism. Binding and infectivity
assays with CHO cells and infectivity assays with mutant viruses were
evaluated for statistically significant differences by one-way ANOVA fol-
lowed by Tukey’s multiple-comparison test. P values of 	0.05 were con-
sidered to be statistically significant. All differences not specifically indi-
cated to be significant were not significant (P 
 0.05). All experiments
were performed in triplicate at least twice.
RESULTS
Inhibition of strain 181/25 infectivity by soluble GAGs. We
hypothesized that CHIKV vaccine strain 181/25 might have be-
come adapted to use GAGs as attachment receptors during pas-
sage in cell culture, as has been demonstrated for other alphavi-
ruses (51–53, 55). We also thought it possible that a clinical isolate
of CHIKV could use GAGs for infectivity, as has been noted for
natural isolates of EEEV and VEEV (50, 62). To assess whether
soluble GAGs act as competitive agonists and block infectivity of
CHIKV strains 181/25 and SL15649, we performed competition
assays using increasing concentrations of different GAGs. Purified
181/25 or SL16549 virions were preincubated with heparin, hepa-
ran sulfate, chondroitin sulfate A, dermatan sulfate, hyaluronic
acid, shark cartilage chondroitin sulfate, or bovine serum albumin
and adsorbed to BHK-21 cells. Cells were scored for infectivity in
a single-round replication assay using indirect immunofluores-
cence. Preincubation of 181/25 with heparin, heparan sulfate,
chondroitin sulfate A, or dermatan sulfate decreased infectivity of
BHK-21 cells in a dose-dependent manner (Fig. 1A). Dermatan
sulfate and heparan sulfate were the most potent inhibitors of
181/25 infectivity in this assay. Chondroitin sulfate A and heparin
were also potent inhibitors of 181/25 infectivity. Hyaluronic acid
and a mixture of chondroitin sulfate A/C/E from shark cartilage
also inhibited 181/25 in a dose-dependent manner (Table 1 and
data not shown). As a control, BSA did not significantly diminish
infectivity at any dose tested (Fig. 1A). In addition, heparin inhib-
ited 181/25 plaque formation in a dose-dependent manner using
plaque-reduction assays (data not shown). We also tested whether
heparin preincubation could inhibit 181/25 produced by C6/36
mosquito cells and found that mosquito-derived virus was inhib-
ited by this soluble GAG in a dose-dependent manner and to an
extent similar to that seen with mammalian-derived 181/25 (data
not shown). Preincubation of 181/25 with soluble GAGs also in-
hibited infectivity of CHO-K1 cells (data not shown), indicating
that the inhibitory effect of GAGs on 181/25 infectivity is not
restricted to BHK-21 cells. Importantly, preincubation of cells
with 500 g/ml of heparin, heparan sulfate, chondroitin sulfate A,
dermatan sulfate, and hyaluronic acid prior to viral infection did
not inhibit infectivity of 181/25 (data not shown). These results
indicate that the inhibitory effect of soluble GAGs is due to inter-
actions with virus and not cells.
In contrast to the 181/25 results, the infectivity of strain
SL15649 was not significantly altered in a dose-dependent manner
by any of the soluble GAGs tested (Fig. 1B and data not shown).
These data indicate that 181/25 and SL15649 differ in susceptibil-
ity to inhibition by soluble GAGs and suggest that these CHIKV
strains exhibit differential interactions with GAGs, possibly in the
affinity for GAGs or in the nature of GAG interactions.
Since the infectivity of strain 181/25 was efficiently inhibited by
GAGs, we next tested whether incubation of virus with soluble
GAGs blocks binding of 181/25 to BHK-21 cells. Purified 181/25
virions were incubated with soluble GAGs prior to adsorption to
BHK-21 cells. Virus binding was assessed using flow cytometry
(Fig. 1C). Higher concentrations of GAGs were used in this assay
since greater numbers of virion particles are required to detect a
fluorescence signal following binding. Similar to the infectivity
results, virus binding to BHK-21 cells was effectively blocked by
preincubation with each of the GAGs tested in a dose-dependent
manner. In this assay, heparin was the most potent inhibitor of
binding of 181/25 to BHK-21 cells. Dermatan sulfate and heparan
sulfate also inhibited binding, as did chondroitin sulfate A, but at
much higher concentrations (Table 1). Differences in the magni-
tude of inhibition by specific soluble GAGs in the infectivity and
binding assays are likely due to differences in assay conditions,
including cell number, virus concentration, temperature, and du-
ration of adsorption. Collectively, these data indicate that soluble
GAGs inhibit infectivity of strain 181/25, but not SL15649, on
BHK-21 cells by blocking 181/25 from binding to the cell surface
and suggest that 181/25 and GAGs directly interact.
Inhibition of 181/25 by soluble heparan sulfate occurs prior
to endosomal escape. To determine whether inhibition of 181/25
infectivity by soluble GAGs occurs during an early step of the entry
process prior to endosomal escape, we defined the temporal win-
dow at which heparan sulfate acts by adding the GAG to virus
inocula at various times during the adsorption phase. Consistent
with our previous observations (Fig. 1A), incubation of 181/25
with heparan sulfate prior to adsorption resulted in almost com-
plete inhibition of 181/25 infectivity (Fig. 2A), whereas incubation
with BSA had no effect (data not shown). Inhibition of 181/25
infectivity by heparan sulfate diminished as a function of time
following viral adsorption. Notably, almost 50% of the inhibitory
effect of heparan sulfate was lost when it was added 20 min post-
adsorption (56% infected cells; P 	 0.01 compared with the BSA
control). When added 45 min after adsorption, heparan sulfate
lost almost all inhibitory effect (88% infected cells; P 	 0.01
compared with the BSA control). These data indicate that heparan
sulfate inhibits 181/25 infectivity early in the infectious cycle.
Since attachment of CHIKV occurs prior to internalization of
the virus into the endocytic pathway, we sought to determine the
time required for 181/25 to escape the endosome and become
resistant to a lysosomotropic agent. We assessed the capacity of
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NH4Cl to inhibit 181/25 infectivity of BHK-21 cells when added at
various times during the adsorption phase (Fig. 2B). NH4Cl raises
the pH of intracellular organelles within 1 min following addition
to the medium (73), thereby allowing inhibition of low-pH-de-
pendent endosomal escape by the virus at defined intervals postin-
fection. BHK-21 cells were adsorbed with 181/25 virions, and me-
dium containing 20 mM NH4Cl was added at various intervals
after adsorption. The percent infected cells at 18 hours postinfec-
tion (hpi) was determined by indirect immunofluorescence and
normalized to the infectivity of 181/25 when NH4Cl was added at
120 min after infection. When NH4Cl was added at 5 min postad-
sorption, only 4.5% of cells were infected by 181/25 (P 	 0.01).
Inhibition of 181/25 infectivity by NH4Cl decreased gradually
over time, with approximately half of the inhibitory effect lost by
45 min postadsorption (P 	 0.01) and all the inhibitory effect lost
by 100 min postadsorption (P 
 0.05). These data confirm previ-
ous observations that endosomal acidification is essential for
CHIKV infection of cells (13, 31–34) and suggest that inhibition of
181/25 infectivity by heparan sulfate occurs prior to inhibition by
NH4Cl.
CHIKV strains 181/25 and SL15649 require cell-surface
GAGs for binding and infectivity. To examine whether GAGs are
required for CHIKV infection, we tested 181/25 and SL15649 for
the capacity to infect parental CHO-K1 cells and a panel of mutant
FIG 1 Soluble GAGs inhibit 181/25 infectivity and binding. (A and B) Purified virions of strain 181/25 (A) or SL15649 (B) (MOI of 2.5 PFU/cell) were
incubated with buffer alone or buffer containing heparin, heparan sulfate, chondroitin sulfate A, dermatan sulfate, or bovine serum albumin (BSA) at the
concentrations shown at 4°C for 30 min prior to adsorption to BHK-21 cells. At 2 hpi, the inoculum was replaced with medium containing 20 mM NH4Cl. At
18 hpi, infected cells were detected by indirect immunofluorescence. Results are expressed as the mean percentage of infected cells normalized to untreated
controls for three (181/25) or two (SL15649) independent experiments performed in triplicate. Error bars indicate SEM. *, P 	 0.05; **, P 	 0.01 (in comparison
to untreated controls as determined by one-way ANOVA followed by Dunnett’s post hoc test). (C) Strain 181/25 (MOI of 5 PFU/cell) was incubated with buffer
alone or buffer containing heparin, heparan sulfate, chondroitin sulfate A, or dermatan sulfate at the concentrations shown at 4°C for 30 min. Virus-GAG
mixtures were adsorbed to BHK-21 cells at 4°C for 30 min and stained with a CHIKV-specific antibody. The MFI of each sample was determined by flow
cytometry. The data were normalized to the MFI of untreated virus controls for three independent experiments performed in triplicate. Error bars indicate SEM.
*, P 	 0.01 (in comparison to untreated controls as determined by one-way ANOVA followed by Dunnett’s post hoc test).
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CHO cells that display various defects in GAG biosynthesis
(Fig. 3A). Parental CHO-K1 and mutant cell lines were adsorbed
with either strain and scored for infectivity using conditions to
allow a single infectious cycle. Cell line pgsA745, which is deficient
in xylosyltransferase activity and thus lacks expression of all GAGs
(74, 75), was highly resistant to infection by 181/25 (0.5% in-
fected cells; P 	 0.001 compared with the CHO-K1 cells), con-
firming previous observations (76). These cells also were resistant
to infection by SL15649 (18% infected cells; P 	 0.001 com-
pared with the CHO-K1 cells). pgsA745 cells were less susceptible
to strain 181/25 than to strain SL1649 (P 	 0.001), suggesting that
181/25 is more dependent than SL15649 on GAGs for efficient
infection. Cell line pgsB761, which is deficient in galactosyltrans-
ferase I and expresses only 5% of the wild-type levels of heparan
sulfate and chondroitin sulfate (75), was highly resistant to 181/25
infection (7% infected cells; P 	 0.001) but highly susceptible to
SL15649 infection, with the infectivity level nearing that of paren-
tal CHO-K1 cells (97% infected cells; P 
 0.05). Similarly, cell
line pgsD677, which is deficient in both N-acetylglucosaminyl-
transferase and glucuronosyltransferase activity and produces a
3-fold excess of chondroitin sulfate but no heparan sulfate (77),
was highly resistant to 181/25 (2% infected cells; P 	 0.001) but
susceptible to SL15649 (70% infected cells; P 	 0.001), albeit
less susceptible than the pgsB761 cell line. These results suggest
that both vaccine strain 181/25 and clinical isolate SL15649 de-
pend on cell-surface GAGs for efficient infection but that the spe-
cific GAGs or structural specificities of the GAGs used by these
viruses may differ.
To determine whether GAGs are required for attachment of
181/25 and SL15649 to CHO cells, we tested both viruses for the
capacity to bind parental and mutant CHO cell lines. Cells were
incubated with either virus strain and scored for binding using
flow cytometry (Fig. 3B). Strain 181/25 did not efficiently bind to
any of the mutant cell lines (P 	 0.001 for pgsA745, pgsB761, and
pgsD677 compared with CHO-K1). In contrast, SL15649 bound
modestly to both pgsB761 and pgsD677 cells (P 	 0.001 for both
cell lines compared with CHO-K1) but less well to pgsA745 cells
(P 	 0.001 compared with CHO-K1). To confirm that CHO-K1
and mutant cell lines can support viral replication if entry steps are
bypassed, we introduced in vitro-transcribed 181/25 RNA into
both CHO-K1 and pgsA745 cells by electroporation and deter-
mined titers of progeny virus in cell supernatants 24 h later. We
found that CHO-K1 and pgsA745 cells produce infectious virus to
similar extents following viral RNA electroporation (data not
TABLE 1 Inhibition of 181/25 infectivity and binding by soluble GAGs
Inhibitor
Infectivity Binding
Inhibition (%)a IC50, g/ml (95% CI)
b Inhibition (%)c IC50, g/ml (95% CI)
b
Heparin 76.4  9.8 248.5 (203.6–303.5) 98.3  1.3 7.9 (3.542–17.74)
Heparan sulfate 95.1  3.4 25.3 (23.3–27.5) 90.9  11.4 357.7 (254.0–503.7)
Chondroitin sulfate A 74.6  13.3 44.5 (34.4–57.5) 96.0  0.6 179.1 (130.6–245.7)
Dermatan sulfate 90.9  6.9 17.5 (15.21–19.35) 60.6  6.5 
750d
Chondroitin sulfate A/C/E 78.2  11.0 9.0 (6.469–12.52) NDe ND
Hyaluronic acid 86.7  8.6 112.3 (97.9–128.8) ND ND
a Percent inhibition of infectivity compared with untreated controls (at a concentration of inhibitor of 500 g/ml)  standard error of the mean.
b Inhibitory concentration of each GAG that prevents 50% of infectivity (IC50) relative to untreated controls with the 95% confidence interval (CI).
c Percent inhibition of binding compared with controls (at a concentration of inhibitor of 1,000 g/ml)  standard error of the mean.
d Could not be determined accurately due to partial dose response.
e ND, not determined.
FIG 2 Kinetics of inhibition of 181/25 by heparan sulfate and ammonium chloride. (A) 181/25 virions (MOI of 2.5 PFU/cell) were adsorbed to BHK-21 cells
at 37°C. At the times shown prior to or during adsorption, heparan sulfate (250 g/ml) was added to the virus inoculum. After 2 h adsorption, unbound virus
was removed, and cells were incubated with medium containing 20 mM NH4Cl. At 18 hpi, infected cells were detected by indirect immunofluorescence. Results
are expressed as the mean percentage of infected cells normalized to BSA-treated controls from two independent experiments performed in triplicate. Error bars
indicate SEM. *, P 	 0.01 (in comparison to BSA-treated controls as determined by one-way ANOVA followed by Dunnett’s post hoc test). (B) 181/25 virions
(MOI of 2.5 PFU/cell) were adsorbed to BHK-21 cells at 37°C. At the times shown following adsorption, the virus inoculum was removed, and cells were
incubated with medium containing 20 mM NH4Cl. At 18 hpi, infected cells were detected by indirect immunofluorescence using a CHIKV-specific polyclonal
antibody. Results are expressed as the mean percentage of infected cells normalized to the percentage of infected cells when NH4Cl was added at 120 min from
three independent experiments performed in triplicate. Error bars indicate SEM. *, P 	 0.01 (in comparison to untreated controls as determined by one-way
ANOVA followed by Dunnett’s post hoc test).
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shown). Together, these data indicate that both vaccine strain
181/25 and clinical isolate SL15649 depend on cell-surface GAGs
for infection, specifically at the stage of viral attachment.
E2 residue 82 influences dependence on cell-surface GAGs.
Although both 181/25 and SL15649 depend to some extent on
cell-surface GAGs for efficient binding and infectivity, these
strains display differences in the requirement for GAG utilization
and inhibition by soluble GAGs. To identify amino acids respon-
sible for these differences, we compared E2 amino acid sequences
of 181/25 and SL15649 and found 16 amino acid polymorphisms
(Table 2). Interestingly, 181/25 E2 contains arginines at residues
82 and 318, whereas SL15649 E2 contains glycine and valine resi-
dues at these positions, respectively. We were particularly inter-
ested in residue 82 because the presence of an arginine at this
position is partially responsible for attenuation of virulent strains
in some mouse models of CHIKV infection (80). To determine
whether differences in GAG utilization between 181/25 and
SL15649 are due to polymorphisms at one or both of these posi-
tions, we generated isogenic variants in the SL15649 and 181/25
infectious clones containing reciprocal amino acid substitutions
at residues 82 and 382 in single- and double-mutant constructs
(Table 3). The rescued viruses were viable, producing cytopathic
effect (CPE) in BHK-21 cells within 24 h of electroporation and
replicating to titers of 107 to 109 PFU/ml of purified virus, which
are comparable to those seen with the parental SL15649 and
181/25 viruses, respectively (Table 3). In these experiments, we
observed a correlation between virus titers in Vero cells and the
amino acid at position 82. 181/25-E2 R82G and -E2 R82G/R318V
virus titers were approximately 6- to 8-fold lower than those of
181/25. Correspondingly, SL15649-E2 G82R and -E2 G82R/
V318R virus titers were approximately 5- to 7-fold higher than
titers of SL15649. Titers for the reciprocal E2 318 mutants were
comparable to those of their parental counterparts. We also ob-
served a small-plaque phenotype for SL15649-E2 G82R and -E2
G82R/V318R compared with SL15649 (data not shown). Of note,
FIG 3 CHIKV 181/25 and SL15649 infectivity of and binding to parental and
mutant CHO cells. (A) Parental CHO-K1, pgsA745, pgsB761, and pgsD677 cells
were adsorbed with an MOI of 10 PFU/cell of either 181/25 or SL15649. At 2 hpi,
the inocula were replaced with medium containing 20 mM NH4Cl. At 18 hpi,
infected cells were detected by indirect immunofluorescence. Results are expressed
as the mean percentage of infected cells normalized to the percentage of infected
parental CHO-K1 cells for three (181/25) or two (SL15649) independent experi-
ments performed in triplicate. Error bars indicate SEM. *, P 	 0.001 (in compar-
ison to the infectivity of the appropriate parental virus in CHO-K1 cells as deter-
mined by one-way ANOVA followed by Tukey’s multiple-comparison test). (B)
Parental CHO-K1, pgsA745, pgsB761, and pgsD677 cells were adsorbed with an
MOI of 5 PFU/cell of either 181/25 or SL15649 at 4°C for 1 h and stained with a
CHIKV-specific antibody. The mean fluorescence intensity (MFI) of each sample
was determined by flow cytometry. The data were normalized to the MFI of virus
bound to parental CHO-K1 cells for three (181/25) or two (SL15649) independent
experiments performed in triplicate. Error bars indicate SEM. *, P 	 0.001 (in
comparison to the binding of the appropriate parental virus to CHO-K1 cells as
determined by one-way ANOVA followed by Tukey’s multiple-comparison test).
GAG, glycosaminoglycan; HS, heparan sulfate; CS, chondroitin sulfate.
TABLE 2 Amino acid polymorphisms in the E2 glycoprotein sequences of viruses used in this study
Virus strain
E2 amino acid at positiona:
2 12 82 118 149 157 164 194 205 255 312 317 318 375 377 384
SL15649 T T G S K V T G G I M V V T I M
181/25 I I R G R A A S D V T I R S V V
a Numbered from the N terminus of E2.









WT 1.58  1011 1.4  109 120 1.0
E2 R82G 7.88  1010 2.2  108 360 3.2
E2 R318V 7.22  1010 1.0  109 72 0.62
E2 R82G/R318V 8.83  1010 1.8  108 500 4.4
SL15649
WT 7.71  1010 1.7  107 4400 1.0
E2 G82R 1.93  1010 1.2  108 160 0.036
E2 V318R 1.51  1011 3.0  107 5100 1.1
E2 G82R/V318R 2.91  1010 8.3  107 350 0.079
a Genomes/ml data were determined by duplicate real-time quantitative PCRs from
three replicate experiments.
b Titers were determined by plaque assay using Vero cells. The mean viral titers from
three independent plaque assays of a single stock are shown.
c Each mutant genome/PFU value was normalized to the parental WT value. The ratio
of the relative numbers of genomes to PFU of WT 181/25 to that of WT SL15649 was
0.027.
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a small-plaque phenotype was originally used as a criterion for
selecting clone 181/25 (65). However, plaques formed by 181/
25-E2 R82G and -E2 R82G/R318V were not correspondingly
larger than those formed by 181/25 (data not shown).
As an additional measure of viral fitness, we determined the
genome/PFU ratio for each virus in infectivity assays using Vero
cells. The parental strains 181/25 and SL15649 had genome/PFU
ratios of 120 and 4,400, respectively (Table 3). E2 318 mutants had
genome/PFU ratios similar to those of the parental strains. How-
ever, variants 181/25-E2 R82G and 181/25-E2 R82G/R318V had
genome/PFU values that were 3.2- and 4.4-fold higher, respec-
tively, than those of 181/25. Correspondingly, SL15469-E2 G82R
and SL15649-E2 G82R/V318R had genome/PFU ratios that were
28- and 13-fold lower, respectively, than those of SL15649. Thus,
an arginine at position 82 in E2 results in increased viral titers, a
decreased genome/PFU ratio, and, in the SL15649 background, a
reduction in plaque size, suggesting that a basic residue at position
82 in E2 enhances viral fitness in mammalian cell culture. A small-
plaque phenotype (51, 58, 59, 65) and a higher level of infectivity
in cell culture (53, 61) have been observed with other GAG-bind-
ing alphavirus strains.
To determine whether either of the basic amino acids at E2 82
and 318 affects GAG utilization, parental and mutant viruses were
tested for infection of parental CHO-K1 and mutant pgsB761
cells, the cell line in which we observed the greatest difference in
infectivity between the two parental strains (Fig. 3A). As before,
SL15649 efficiently infected pgsB761 cells (95% infected),
whereas infection of these cells was greatly impaired for 181/25
(8%) relative to infection of parental CHO-K1 cells (P 	 0.001
for both viruses) (Fig. 4). Substitution of Arg82 with a glycine in
181/25 E2 (181/25-E2 R82G) allowed efficient infection of
pgsB761 cells (82% infected; P 	 0.001 compared with 181/25),
whereas substitution of Gly82 in SL15649 E2 with an arginine
(SL15649-E2 G82R) resulted in substantially reduced infectivity
of these cells (5% infected; P 	 0.001 compared with SL15649).
Substitution of Arg318 in 181/25 E2 with valine (181/25-E2
R318V) or of Val318 in SL15649 E2 with arginine (SL15649-E2
V318R) resulted in increased infectivity of pgsB761 cells (28%
or 128% infected, respectively). The SL15649-E2 G82R/V318R
double mutant did not efficiently infect pgsB761 cells (4% in-
fected; P 	 0.001 compared with SL15649), whereas the 181/
25-E2 R82G/R318V double mutant did (88% infected; P 	 0.001
compared with 181/25), suggesting that the sequence polymorphism
at residue 82 predominates in conferring infectivity of pgsB761 cells.
Therefore, an arginine at E2 residue 82 yields a higher degree of de-
pendence on cell-surface GAGs for efficient infection.
E2 R82 mediates a direct interaction with GAGs. Since cell-
surface GAGs are required for efficient binding and infectivity by
181/25 and SL15649, we next tested whether CHIKV virions and
GAGs directly interact. Equivalent genome copies (5  107) of
purified 181/25, 181/25-E2 R82G, SL15649, or SL15649-E2 G82R
virions were incubated with agarose beads conjugated to heparin
or with unconjugated beads as a negative control, and bound ma-
terial from both heparin-agarose and unconjugated beads was re-
solved by SDS-PAGE and transferred to a PVDF membrane.
Membranes were immunoblotted using an anti-E2 antibody to
detect captured virus. We found that 181/25 was efficiently cap-
tured by heparin-agarose beads, whereas 181/25-E2 R82G was not
(Fig. 5A). Correspondingly, we observed little capture of SL15649
by heparin beads, while SL15649-E2 G82R was more efficiently
precipitated (Fig. 5A). We detected no virus capture by beads
alone, suggesting that interactions between heparin and virions
are specific (Fig. 5B). Densitometric analysis of three independent
experiments indicates that 38% and 24% of 181/25 and
SL15649-E2 G82R, respectively, were captured by heparin-aga-
rose beads (Fig. 5C). In contrast, SL15649 and 181/25-E2 G82R
displayed low levels (5%) of binding to heparin (Fig. 5C). We
conclude that CHIKV virions directly interact with heparin and
that this interaction is greatly enhanced by the presence of a basic
residue at position 82 in the E2 glycoprotein.
Structural and sequence analysis of CHIKV E2 82. Since in-
teractions between GAGs and proteins often occur via electro-
static and hydrogen-bond interactions between anionic (carbox-
ylate and sulfate) groups in GAGs and cationic amino acid side
FIG 4 E2 residue 82 is a primary determinant of GAG utilization. Parental CHO-K1 and pgsB761 cells were adsorbed with an MOI of 10 PFU/cell of
each parental virus (181/25 or SL15649) or the E2 mutants shown. At 2 hpi, the inoculum was replaced with medium containing 20 mM NH4Cl. At 18 hpi,
infected cells were detected by indirect immunofluorescence. Results are expressed as the mean percentage of infected pgsB71 cells normalized to parental
CHO-K1 cells for each virus for two independent experiments performed in triplicate. Error bars indicate SEM. *, P 	 0.001 (in comparison to infectivity
of the appropriate parental virus in CHO-K1 cells as determined by one-way ANOVA followed by Tukey’s multiple-comparison test).
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chains, we sought to determine how substitution of Gly82 to Arg
affects the local electrostatic environment surrounding this resi-
due. Using the crystal structure of the CHIKV E1/E2 trimer (Pro-
tein Data Bank [PDB] accession code 2XFB [30]), we modeled the
181/25 E2 structure by substituting 12 residues of the 16 total
polymorphisms displayed by the two strains (Table 2) located
within the crystal structure, including G82R. The electrostatic
charge distribution for each virus was calculated using the PyMol
plug-in program APBS (71) and mapped onto a molecular surface
representation of the E1/E2 trimer (Fig. 6). In the SL15649 model
of the E1/E2 trimer (Fig. 6A and B, left panels), Gly82 is located in
the “wings” insertion in the BC loop at the top of the immuno-
globulin-like -barrel fold that comprises domain A of E2, which
has been implicated in mediating interactions with receptors (30).
Gly82 is part of a cavity formed by domain A, which is centered on
the 3-fold axis of the trimer spike. The three Gly82 residues are
located at the inner apical surface of the cavity, facing toward the
cavity center (Fig. 6A and B). Substitution of glycine with an argi-
nine at residue 82 results in an expected increase in positive charge
of the environment surrounding this residue (Fig. 6B). In addi-
tion, the additional density of the larger arginine side chain occu-
pies a space adjacent to a conserved lysine at position 120, which is
vacant in the SL16549 structure (Fig. 6C). Since residue 82 is part
of the central cavity, it is possible that the increase in positive
charge at this position in 181/25 results in formation of a GAG-
binding pocket at the central cavity apex.
We surveyed the frequency of an arginine or glycine at E2 82 in
historical and circulating CHIKV strains. Alignment of the 158
CHIKV E2 protein sequences available in the NIAID ViPR data-
base (72) revealed that 157 of 158 (
99%) sequences contained a
glycine at position 82 in E2. The only sequence in the database that
contains an arginine at this residue is 181/25 (TSI-GSD-218 [65,
67]). CHIKV11, a strain isolated from an infected patient in Sin-
gapore in 2006, is the only other published CHIKV strain that has
an arginine at position 82 in E2 (78). CHIKV11 was passaged in
Vero cells and may have acquired an arginine at position 82 during
cell-culture passage (78). This analysis reveals that a glycine at
residue 82 in E2 is highly conserved.
FIG 5 CHIKV E2 R82G mediates a direct interaction with heparin. Approxi-
mately 5  107 genome equivalents of purified 181/25, 181/25-E2 R82G, SL15649,
and SL15649-E2 G82R virions were incubated with 75 l of washed heparin-
agarose beads (A) or unconjugated beads (B) at 4°C for 30 min. Beads were washed
three times, and the bound material as well as 12.5% of the input virus was resolved
by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted for E2 as a
marker for captured virus using a CHIKV-specific monoclonal antibody. The
results of an experiment representative of three performed are shown. P, parental
virus. (C) Densitometric analysis of virus bound to heparin-agarose beads. Data
are expressed as the mean percent bound virus calculated from the densitometric
analysis of captured virus divided by the estimated total input virus for three in-
dependent experiments. Error bars indicate SEM.
FIG 6 Electrostatic potentials of SL15649 and 181/25 E1/E2 trimers. (A) Top view
of the electrostatic potential map displayed on the molecular surface of E1/E2
trimers of SL15649 (left panel) compared with a model of 181/25 (right panel)
based on the crystal structure of CHIKV E1/E2 (PDB accession no. 2XFB). Positive
potential is depicted in blue, and negative potential is depicted in red. (B) Enlarged
view of the boxed areas from panel A highlighting the central cavity of the E1/E2
trimer. A white arrow indicates the position of Gly82 in SL15649 (left panel) or
Arg82 in 181/25 (right panel) in one of the E2 monomers. (C) Enlarged view of the
inner cavity rotated by 90° around the horizontal axis from the top view in panel B.
A ribbon tracing of E2 is shown with a semitransparent view of the electrostatic
surface and amino acids Gly82 (SL15649, left panel) or Arg82 (181/25, right panel)
and Lys120 shown in stick representations.
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DISCUSSION
The initial events in the replication cycle of CHIKV are not well
defined. In this study, we found that CHIKV vaccine strain 181/25
requires cell-surface glycosaminoglycans for efficient attachment
to and infection of cells in culture. In addition to pgsA745 cells,
which are not susceptible to 181/25 infection (76), pgsB761 cells
or pgsD677 cells are likewise not susceptible to 181/25 infection,
suggesting that 181/25 is dependent on cell-surface heparan sul-
fate for efficient infection. We detected decreased cell binding by
181/25 both in the absence of cell-surface GAGs and in the pres-
ence of soluble GAGs. Moreover, we found that inhibition of
181/25 infectivity by soluble heparan sulfate occurs prior to endo-
somal escape. Collectively, these data suggest that 181/25 uses
heparan sulfate proteoglycans as attachment receptors.
Our structural analysis suggests that Arg82 participates in a
solvent-accessible GAG-binding pocket in the central cavity of the
E1/E2 trimer of 181/25. Although the precise GAG-binding site
cannot be determined without high-resolution structural studies
of 181/25 with a soluble GAG, it is likely that a number of basic
amino acids in E2 coordinate interactions with GAGs (46, 49, 79).
We think it likely that Arg82 participates in a network of basic
residues, possibly including Lys120, which form a GAG-binding
site in 181/25 E2 and enhances the affinity of the glycoprotein for
GAGs. In support of this model, 181/25 bound heparin more ef-
ficiently than did SL15649. In addition, substitution of Gly82 with
Arg in SL15649 increased virus binding to heparin, suggesting an
increase in E2 affinity for GAGs.
It has been hypothesized that Arg82 in E2 of 181/25 contributes
to attenuation of the vaccine strain due to GAG binding (76, 80).
Our results provide support for this hypothesis. An arginine at
position 82 in both 181/25 and SL15649 results in a greater depen-
dence on GAGs for infection in cell culture. In addition, we pro-
vide the first evidence for a direct interaction between 181/25 and
an immobilized GAG, which is highly dependent on the presence
of an arginine at position 82 in E2. In comparison to its parental
strain AF15561, 181/25 contains 10 nucleotide differences, in-
cluding two amino acid polymorphisms in the E2 glycoprotein
(T12I and G82R) (80). Genetic analysis reveals that E2 T12I and
G82R are responsible for attenuation of both AF15661 and a clin-
ical isolate, CHIKV LR2006 OPY-1 (strain LR), in mouse models
of CHIKV virulence (80), indicating that Arg82 in E2 functions in
attenuation of CHIKV. Although infection of mice with 181/25
results in decreased dissemination and viremia compared with
parental strain AF15561 or strain LR (76, 80), mechanisms of vir-
ulence attenuation of 181/25 in vivo have not been fully eluci-
dated. Similar to other GAG-binding viruses, low levels of viremia
during infection with 181/25 may be due to rapid clearance of
virus from the bloodstream (55, 58, 81–83).
The conservation of a glycine at position 82 in E2 suggests that
this residue contributes importantly to viral fitness. Consistent
with this idea, 181/25 infects A. albopictus C6/36 cells less effi-
ciently than its parental virus AF15561, which contains Gly82 (data
not shown), suggesting that an arginine at this position in E2
brings a fitness cost for replication of CHIKV in mosquito cells. In
addition, evidence of reversion from Arg to Gly at position 82
in E2 of 181/25 was observed during infections of mice (80) and in
one viremic vaccinee during phase II clinical trials (67), indicating
that Gly82 is selected for in vivo. It is possible that the presence of
Arg82 may alter the tertiary structure of E2, which may affect bind-
ing to other mosquito or mammalian cell receptors.
Similar to other low-passage-number isolates of EEEV and
VEEV (50, 62), CHIKV SL15649 exhibits dependence on cell-sur-
face GAGs for efficient binding and infection in cell culture. How-
ever, GAG binding may not be a property of all CHIKV strains.
For example, it has been demonstrated that CHIKV strain LR
replicon particles do not depend on cell-surface GAGs for infec-
tion (76). It is unclear whether the observed difference between
SL15649 and LR in GAG dependence is due to sequence polymor-
phisms or experimental differences. Sequence analysis of the in-
fectious clone of SL15649 did not reveal the presence of additional
basic amino acids in E2 compared with other clinical isolates (data
not shown), suggesting that the requirement for cell-surface
GAGs for efficient infection of SL15469 is not the result of cell
culture adaptation.
Our experiments using CHO cells deficient in various GAGs
provide evidence that 181/25 and SL15649 are dependent on
GAGs to differing extents for efficient infection. While it is possi-
ble that abrogation of GAG expression in mutant CHO cells alters
the expression of other cell-surface molecules required for CHIKV
binding, we think this is unlikely since CHIKV strain LR readily
infects these cells (76). Interestingly, we did not detect inhibition
of SL15649 infectivity by soluble GAGs. SL15649 may bind to
GAGs only within the context of a proteoglycan or when ex-
pressed at the cell surface. However, we observed a low level of
binding of SL15649 to immobilized heparin, which is likely due to
interactions between virions and heparin and not a consequence
of nonspecific binding to beads, since virus did not bind beads
alone. Physiologically relevant GAG-protein interactions display
affinities that can range from rather weak (dissociation constant
[Kd] 
 10
6 M) to moderately strong (Kd  10
9 M) (46).
Although mounting evidence suggests that high-affinity interac-
tions with GAGs diminish alphavirus virulence (50, 55, 57–59,
63), low-affinity interactions with GAGs may be important for
replication within hosts (e.g., to mediate attachment in specific
tissues) and consequent pathology.
The structural specificity of the interactions between viruses
and GAGs is poorly understood (reviewed in references 84 and
85). GAGs are heterogenous and differ in chain lengths, sulfation
patterns, and subunit configurations due to the spatiotemporal
expression patterns of GAG biosynthesis genes (79, 85, 86). The
presence of specific subunits (e.g., iduronic acid) (44, 87) or the
extent and position of sulfation of particular GAGs (39, 88, 89)
can substantially influence the specificity of virus-GAG interac-
tions. GAG-binding sites on proteins are surface exposed or in
shallow grooves containing positively charged amino acids. The
precise spacing of cationic clusters and the composition and ar-
rangement of other residues that comprise the local environment
of the GAG-binding site are important for specificity of interac-
tions with GAGs (49, 90). Strain variants that contain basic resi-
dues that mediate some level of GAG binding among the different
alphaviruses map to five surface-exposed regions within E2: resi-
dues 1 to 4 (53–55, 62), 70 to 82 (50, 53–55, 58–60), 114 to 120 (53,
55, 62), 157 to 161 (58), and 209 to 218 (51, 55). Although it is
thought that alphavirus E1 and E2 trimers adopt similar overall
folds (30, 91), it is possible that the spacing and location of the
GAG-binding residues and the local amino acid environment of
these five regions in E2 contribute to the type and specificity of
GAG-E2 interactions. Conserved basic residues are often found
Silva et al.
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within or near these five sites, which may mediate low-affinity
interactions with GAGs. Basic amino acid polymorphisms within
these regions of E2 from passaged viruses or natural isolates may
increase the affinity of E2 for different GAGs or alter GAG-bind-
ing specificity.
Studies of interactions between GAGs and other alphaviruses
have mainly focused on heparin or heparan sulfate. However,
studies using other soluble GAGs suggest that some strains use
GAGs other than heparan sulfate to bind cells. For example, SINV
strain Toto1101 binds to and is inhibited by soluble dermatan
sulfate in addition to heparin (52). Similarly, a subset of VEEV
GAG-binding mutants inhibited by soluble heparin are also inhib-
ited by soluble dermatan sulfate (55). Differences in structural
specificities of GAG interactions with alphavirus E2 glycoproteins
may influence the tropism and pathology of these GAG-binding
viruses. Indeed, this idea is supported by a study of EEEV heparan
sulfate-binding mutants (59).
Our data suggest that 181/25 and SL15649 differ in the utiliza-
tion of individual GAGs or structural specificities of GAGs. Al-
though 181/25 infectivity was inhibited to some extent by all sol-
uble GAGs tested, regardless of type of subunits or level of
sulfation, this virus displays greater GAG specificity in cell culture.
Based on studies using mutant CHO cell lines, strain 181/25 ap-
pears to depend mainly on heparan sulfate in cell culture, whereas
SL15649 appears to use chondroitin sulfate, possibly in addition
to heparan sulfate, for infection. Whether the amino acid se-
quences that influence GAG dependence for 181/25 and SL15649
are distinct or contiguous remains to be determined. Interestingly,
E2 from 181/25 and SL15469 contains a heparin-binding consen-
sus sequence (47) (from residues 250 to 255 [DRKGKI]) which is
solvent accessible and conserved in other circulating CHIKV iso-
lates. Ongoing work to define GAG-binding sites and structural
specificity of GAG interactions with CHIKV 181/25 and virulent
clinical isolates will enhance an understanding of CHIKV tropism
and pathogenesis.
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